ADORA2A and colorectal cancer: Compared to single agent treatment, dual blockade of A2AR and PD-1 pathways exhibited a significant improvement in immune response restoration, tumor growth inhibition and survival in preclinical models of breast and colorectal cancer (39, 67, 74, 76).